Study of tulmimetostat and luxdegalutamide for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new combination of two drugs for men whose prostate cancer has spread and is no longer controlled by hormone therapy. The study aims to see if this treatment can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- Your prostate cancer has spread to other parts of the body and is getting worse despite hormone therapy.
- You have already tried at least one newer hormone therapy drug (like abiraterone, enzalutamide, darolutamide, or apalutamide).
- You have not taken any drug that targets a protein complex called PRC2 (such as EZH2 inhibitors).
- You have not had a type of treatment called radioligand therapy for your prostate cancer (unless you are in a specific part of the study).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two study drugs for people with advanced prostate cancer that has spread or is no longer responding to hormone therapy. The goal is to see if the combination is safe and works against the cancer.
This study tests two different combinations of drugs for men with prostate cancer that has spread to other parts of the body but still responds to hormone therapy. It compares a new pill (tulmimetostat) combined with standard treatments like darolutamide or abiraterone to see if it can help control the cancer longer.
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a new combination therapy for advanced prostate cancer that has stopped responding to standard hormone treatments. It combines a radioactive targeted treatment (Lutetium-177 DGUL) with an immunotherapy drug (pembrolizumab) to see if it can shrink tumors and slow the cancer's growth.
This trial tests a new combination of two drugs for men with advanced prostate cancer that has stopped responding to standard hormone therapy or chemotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
Hear when a new Progressive Metastatic Castrate Resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.